Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

This is a prospective, single-arm, phase Ia clinical study, which was designed to evaluate the efficacy and safety of Pemetrexed Combined With Bevacizumab Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC.

Trial Details

NCT ID
NCT06663306
Phase
PHASE1
Sponsor
Shanghai Chest Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Pemetrexed
  • Bevacizumab
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Age ≥ 18 years;
  • ECOG PS score 0-3. ECOG PS score 2 or 3 should be due to leptomeningeal metastases.
  • Patients with pathologically diagnosed non-small cell lung cancer with cerebrospinal fluid and/or MRI diagnosis of leptomeningeal metastasis(LM);
  • Unsatisfactory efficacy of LM,which defined as disease progression in LM,or LM-related neurological progression, while patients received standard s…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →